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ABSTRACT Microbial communities in the airways of persons with CF (pwCF) are vari-
able, may include genera that are not typically associated with CF, and their composi-
tion can be difficult to correlate with long-term disease outcomes. Leveraging two large
data sets characterizing sputum communities of 167 pwCF and associated metadata, we
identified five bacterial community types. These communities explain 24% of the vari-
ability in lung function in this cohort, far more than single factors like Simpson diversity,
which explains only 4%. Subjects with Pseudomonas-dominated communities tended to
be older and have reduced percent predicted FEV1 (ppFEV1) compared to subjects with
Streptococcus-dominated communities, consistent with previous findings. To assess the
predictive power of these five communities in a longitudinal setting, we used random
forests to classify 346 additional samples from 24 subjects observed 8 years on average
in a range of clinical states. Subjects with mild disease were more likely to be observed
at baseline, that is, not in the context of a pulmonary exacerbation, and community
structure in these subjects was more self-similar over time, as measured by Bray-Curtis
distance. Interestingly, we found that subjects with mild disease were more likely to
remain in a mixed Pseudomonas community, providing some support for the climax-
attack model of the CF airway. In contrast, patients with worse outcomes were more
likely to show shifts among community types. Our results suggest that bacterial commu-
nity instability may be a risk factor for lung function decline and indicates the need to
understand factors that drive shifts in community composition.
IMPORTANCE While much research supports a polymicrobial view of the CF airway,
one in which the community is seen as the pathogenic unit, only controlled experi-
ments using model bacterial communities can unravel the mechanistic role played
by different communities. This report uses a large data set to identify a small number
of communities as a starting point in the development of tractable model systems. We
describe a set of five communities that explain 24% of the variability in lung function in
our data set, far more than single factors like Simpson diversity, which explained only
4%. In addition, we report that patients with severe disease experienced more shifts
among community types, suggesting that bacterial community instability may be a risk
factor for lung function decline. Together, these findings provide a proof of principle for
selecting bacterial community model systems.
KEYWORDS cystic fibrosis, lung infection, microbial communities
Cystic fibrosis (CF) is a genetic disease affecting about 30,000 people in the UnitedStates and 70,000 worldwide (1). It has long been recognized that airway infection
by Pseudomonas aeruginosa predicts morbidity and mortality in young children with
CF (2). Direct sampling of the CF airway demonstrates that a small set of established CF
pathogens such as Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influ-
enzae, and species from the genera Burkholderia, Stenotrophomonas, and Achromobacter
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dominate early infections in children with CF (3). The prevalence of Pseudomonas infection
in the CF community increases with age (4), and it has been reported that few pathogens
other than Pseudomonas are detectable in end-stage disease (5). Not surprisingly, the pre-
vailing thought was once that CF lung disease might be caused by a single pathogen (6,
7), although not necessarily the same pathogen in all people (8). Consequently, treatments
were directed at specific pathogens such P. aeruginosa, S. aureus, and H. influenzae (9).
Evidence from the last 15 years demonstrates that genera outside the established set of CF
pathogens, such as Streptococcus and anaerobes like Prevotella and Veillonella, also play
important roles in lung disease for persons with CF (pwCF) (10–12).
CF lung disease is now considered a polymicrobial phenomenon (13) that can be
described using ecological concepts like species diversity. Diversity has been associ-
ated with improved lung function (14–17), but increased diversity may also signal the
onset of exacerbation (18). Longitudinal analysis, in which a pwCF is followed over
time, generally reveals that the CF airway microbiome is relatively stable (18–21) and
changes modestly during cycles of antibiotic treatment and pulmonary exacerbations,
acute phenomena characterized by a rapid decline in overall health, accompanied by
decreased lung function (19, 22–24). During exacerbations, pwCF experience rapid
decline in overall health, frequently accompanied by permanently decreased lung
function (19). More frequent exacerbations, and failure to recover fully from these exac-
erbations, are thought to differentiate people with moderate or severe disease from
those with mild CF lung disease (25, 26). Intravenous antibiotic treatment in a hospital
setting is recommended during a pulmonary exacerbation and recovery usually occurs
over a period of weeks (21). Complete recovery of lung function to levels prior to exac-
erbation is more common in younger pwCF and those with fewer exacerbations (22).
Recovery may be mediated by response to antibiotics like tobramycin, which is at least
partly predictable from polymicrobial signatures (23). It is possible that some exacerba-
tions are triggered by increasing relative abundance of anaerobes in the two weeks
leading up to an exacerbation (24) or by specific species of Streptococcus, including
anginosus group streptococci (AGS), also known as the milleri group streptococci
(25–27). Collectively, recent findings paint a complex picture of how exacerbations
occur in CF.
One model for how dynamic changes in the CF airway community might be associ-
ated with changes in patient health suggests that the CF airway microbiome is nor-
mally a stable climax community (28) dominated by a classic pathogen such as
Pseudomonas, Achromobacter, or Staphylococcus. From time to time, the intrusion of facul-
tative or obligate anaerobes, via an undescribed mechanism, leads to a fermentative
“attack community” that lowers pH and favors further expansion of anaerobes (28). This
population shift would increase bacterial species diversity, consistent with the increased di-
versity during exacerbation that has been previously observed (18). Interestingly, this is
one instance where increased diversity is associated with a worse clinical outcome rather
than better outcomes, as is typically reported (14, 17, 29–31). Furthermore, the climax-
attack model (CAM) is also consistent with the concept of stable core and dynamic satellite
taxa (16), because these satellite taxa are largely the same genera that are thought to con-
stitute the attack community and it has been shown that satellite genera are more
dynamic across disease states (32).
The primary aim of this study was to improve our understanding of the baseline
community types, including (i) identifying discrete CF airway community types; (ii)
assessing whether community types are associated with different health outcomes; (iii)
describing how community types in pwCF change over time; and (iv) whether commu-
nity stability is associated with disease severity. This analysis included a variety of
machine learning techniques applied to both cross-sectional and longitudinal data
sets. Collectively, our results are consistent with a recent report that bacterial commun-
ities in stable patients have less variation in community structure over time (33), and
our results support the climax-attack model of CF airway disease (28). In addition, we
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identify a five-community model that accounts for 24% of the variability in lung func-
tion, far more than any single factors explored previously.
RESULTS
Five clusters to explain two large cross-sectional data sets. As the emphasis in
CF airway microbiome investigation has shifted toward a polymicrobial interpretation
(13), data analysis has increasingly focused on multivariate comparisons. We therefore
began our analysis to identify polymicrobial community clusters by calculating Bray-
Curtis dissimilarity (34) between genus level taxonomic assignments in bacterial 16S
rRNA gene amplicon sequencing data from 167 sputum samples from people with CF.
Bray-Curtis dissimilarity is a common measure used to compare microbial communities
and places a larger weight on species that are commonly observed, partly mitigating
the problem of random sampling errors associated with rare species. Samples for this
analysis were chosen as a cross-sectional subset of two recently published studies (17,
18) and included clinically stable subjects aged 8 to 69 from 14 CF centers in the
United States and Europe, creating a snapshot that should include many of the com-
munity types present in pwCF. We calculated the Bray-Curtis dissimilarity across 167
cross-sectional samples from these two independent studies: (i) a cross-sectional study
from Cuthbertson et al. (17), from which 83 samples were analyzed, and (ii) a longitudi-
nal study by Carmody et al. (18), from which we selected a single representative sam-
ple from each patient for this analysis (84 samples).
We next used k-means to cluster samples using the Bray-Curtis dissimilarity matrix
we generated above. The k-means machine learning algorithm requires the user to
identify how many clusters (k) are to be identified in the data, then uses an iterative
approach to assign samples to each cluster to minimize distances between samples in
the same cluster and maximize distances between samples in different clusters. Such
machine learning approaches are commonly applied to microbiome studies (35). For
example, unsupervised techniques like hierarchical clustering (36) have been used to
identify core taxa in the CF airway (16) and gut (37) and to demonstrate that samples
from the same person tend to be similar to each other, even across disease and treat-
ment (38). K-means analysis has also been used to identify groups of patients with sim-
ilar patterns in inflammation, microbiota, or clinical factors (39). What makes k-means
unsupervised is that similarity between clusters is based only on observed data, in this
case, counts of bacterial genera. Unsupervised learning does not take sample labels (e.g.,
“severe disease” or “exacerbation”) into consideration. Therefore, when unsupervised clus-
tering places samples labeled “severe disease” together, it is likely that a nonrandom pro-
cess (e.g., the result of a biological difference) caused the samples to cluster.
As described above, the k-means algorithm requires the user to identify how many
clusters (k) are to be identified in the data. Since we had no prior information to justify
a particular choice of k, we used another machine learning approach, the gap statistic
(40), to estimate the number of distinct clusters in our cross-sectional data. The gap
statistic has recently been used to evaluate the optimal number of clusters in CF airway
microbiome data (29). The gap statistic identifies the smallest value of k that minimizes
distances between samples in the same cluster and maximizes distances between sam-
ples. Gap analysis suggested the existence of five distinct community types in our
cross-sectional data set of the 167 baseline samples analyzed here. We found that sub-
jects belonging to different communities also differed significantly in lung function
(see below); this finding suggests that clusters are based on biological differences (39)
and that community types may be clinically relevant. The optimal number of clusters
(five) chosen by the gap statistic algorithm is shown by the vertical dashed line in
Fig. 1A. The basis of this choice is driven by the break in the data after k=5. Specifically,
before k=5, the gap statistic increases, but at k=6, the gap statistic decreases. It is this
deflection, however brief, that the algorithm is designed to detect, because the goal is to
identify the smallest k that is supported by the data. A parsimonious choice of k serves our
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purposes as well, as we seek to identify a small set of distinct communities with relatively
few members to eventually validate in a laboratory setting.
A principal coordinate analysis that captures .70% of the variance of these data
(Fig. 1B) shows how the clusters separate into 5 largely nonoverlapping groups. It is im-
portant to note that this analysis raises the possibility of alternative, potentially equally
valid, grouping of the samples and/or potential overlap among these communities.
It is reassuring that choosing 5 clusters also optimizes the ability of communities to
explain patient differences in lung function. Figure 1C shows the value of adjusted r2
from linear models of ppFEV1, a measure of lung health, as a function of cluster mem-
bership. Five clusters explain about 24% (adjusted r2 = 0.24) of patient differences;
using six clusters reduces r2. In summary, two independent lines of evidence suggest
that as few as 5 clusters may be optimal for summarizing these data.
Cluster membership predicts lung function better than Pseudomonas relative
abundance, age, or community diversity. Despite a reframing of the conversation
surrounding the CF airway microbiome away from single pathogens toward ecological
descriptions involving species diversity (14, 17, 18, 41, 42), the relationship between
Pseudomonas and lung function is still frequently cited (14, 23, 42, 43). We used linear
models to assess the level of association between lung function and commonly identi-
fied explanatory variables such as the relative abundance of Pseudomonas, as well as
Simpson diversity and age. Although sex and cystic fibrosis transmembrane conduct-
ance regulator (CFTR) mutation were present in the van der Gast data set (17), these
annotations were not part of the Carmody data set (18), therefore these covariates
were not included in our analysis. As shown in Fig. 2, single variables like relative abun-
dance of Pseudomonas, Simpson diversity, and age explain less than 11% of patient
variability in lung function (adjusted r2 , 0.11). In other words, over 89% of variability
FIG 2 Microbial clusters are the best predictor of airway function. The ability of linear models to
predict ppFEV1, as estimated by adjusted R squared. Individual factors or combinations (denoted by
“1”) of covariates are shown on the y axis: Simpson diversity only, age only, Pseudomonas only, the
combination of Simpson and age, or Simpson and age and the relative abundance of other classic CF
pathogens, compared to membership in one of the 5 clusters.
FIG 1 Determining cluster numbers. (A) Gap statistic for different numbers of k clusters, ranging from 1 to 10. Larger
values indicate greater separation between clusters. An optimal number of clusters based on gap statistic is shown by
a dashed vertical line. (B) Principal coordinate analysis of 5 clusters, based on the Bray-Curtis dissimilarity matrix. The
legend showing the color code of each cluster is on the right. Together, the first two principal coordinates capture
.70% of the variance in these data. Each dot represents one of 167 samples in the cross-sectional analysis described
in the Materials and Methods. (C) Adjusted r squared from linear models of lung function (ppFEV1) using
membership in a given cluster as the independent variable. Models were run for different numbers of k
clusters, ranging from 2 to 10.
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in lung function is explained by factors other than Pseudomonas, Simpson diversity, or
age. The explanatory power of these models improves with increasing complexity, but
a combined model that incorporates Simpson diversity, age, and the relative abun-
dance of Pseudomonas or other classical CF pathogens in a single model still only
explains less than 12% of patient variability in lung function. In contrast, membership
in one of the 5 communities identified above explains 24% of patient variability in
lung function, without including any other covariates. Adding age or Simpson diversity
to the community model did not significantly improve its predictive power. In other words,
knowing which cluster a person’s airway microbiome belongs to provides a better esti-
mate of their lung function than knowing the relative abundance of Pseudomonas in their
airway microbiome, the diversity of their community, or their age (Fig. 2).
Top 10 bacterial genera across clusters.We identified the top 10 genera with the
highest mean relative abundance across the 167 cross-sectional samples and averaged
their relative abundance in each of the 5 clusters, as shown in Fig. 3A. These 10 genera
accounted for 87% of the relative abundance in cluster 1 (Str.D), to which 46 samples
belonged. This cluster was dominated by Streptococcus (brick red). It is noteworthy
that this cluster was almost exclusively identified in the Carmody (18) data set, which
contained a younger group of subjects. Cluster 2 (Pa.D, 27 samples) was dominated by
Pseudomonas (olive), cluster 3 (Oth.D, 37 samples) was dominated by a genus other
than Pseudomonas or Streptococcus and could be described as having an even mix of
genera based on averages, and cluster 4 (27 samples, Pa.M1) and cluster 5 (30 samples,
Pa.M2) were both dominated by Pseudomonas but were more mixed in nature than Pa.
D. The three Pseudomonas clusters differ in abundance and/or type of minor genera.
While cluster 4 (Pa.M1) and cluster 5 (Pa.M2) were similar, they clustered separately, per-
haps because cluster 5 had more Achromobacter and Burkholderia than cluster 4
(P, 0.001 asymptotic Wilcoxon-Mann-Whitney test), and cluster 4 had more Streptococcus
(P, 0.001, asymptotic Wilcoxon-Mann-Whitney test).
We then mapped each of these clusters back to the two cross-sectional data sets, as
shown in Table 1. The Carmody data set (18) was from a single CF center in the United
States, and the Cuthbertson data set (17) included subjects from Europe and the
FIG 3 Analysis of five identified clusters. (A) Mean abundances of the top 10 genera in each of the 5 clusters.
Mnemonic abbreviations: Str.D, Streptococcus dominated; Pa.D, Pseudomonas dominated; Oth.D, Other dominated;
Pa.M1,Pseudomonas mixed community number 1; Pa.M2,Pseudomonas mixed community number 2. The number
of samples that belonged to each cluster appears beneath each cluster mnemonic. (B) Abundances of the top 10
genera for samples belonging to cluster 3 (Oth.D) in each of the 37 samples belonging to this group. (C) Maximum
abundance of 10 genera achieving the highest relative abundance in any of the 167 samples, as a function of
cluster.
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United States, spanning 13 different CF centers. Some clusters, but not others, were
enriched in data from particular studies, perhaps as a consequence of biases in sample
collection/processing, differences in subject age, and/or systematic differences in
patient care. Of note, the two P. aeruginosa mixed communities, Pa.M1 and Pa.M2,
largely clustered as a function of the data set from which they were derived. Interestingly,
the Carmody (18) data set had no patients in the P. aeruginosa dominant cluster (cluster 2,
Pa.D), while the Cuthbertson (17) samples, collected over 13 centers, had;one-third of its
samples map to this community cluster. In contrast, for the communities assigned to the
Carmody data set (18), more than half were described as Streptococcus-dominated, while
the remaining samples, though containing P. aeruginosa, were more evenly mixed (Pa.M1)
or dominated by other pathogens (Oth.D).
It is likely that both technical and clinical differences contribute to compositional
differences observed between studies. On the one hand, it is well established that CF
practices and outcomes differ by region, both within and between continents (44),
suggesting that CF airway microbiomes may be systematically different by region. On
the other, it is well established that technical differences can cause apparent differen-
ces in community composition (45). A future study of regional CF airway microbiome dif-
ferences, one in which all samples were processed identically, would be required to deter-
mine whether microbiomes truly cluster by geographic location.
Interestingly, averages do not capture the specifics of a group perfectly, as shown
in Fig. 3B. Individual samples that mapped to cluster 3 (Oth.D; Other dominated),
which, when averaged, appear to have an even mix of genera, tended to be dominated
by individual genera, including Stenotrophomonas, which was not among the top 10
most abundant genera across all 167 samples. A sample-by-sample analysis of domi-
nance revealed that Haemophilus, Stenotrophomonas, Burkholderia, Prevotella, and
Achromobacter all achieved high levels of dominance (relative abundance greater than
85%) in cluster 3, but not in other clusters (Fig. 3C). Streptococcus achieved dominance
in cluster 1, but not elsewhere.
Clusters dominated by Streptococcus and Pseudomonas differ in lung function
and age. It has previously been observed that species from the Streptococcus genus
are part of the core CF airway microbiome (16, 31, 43), and that the prevalence of
Streptococcus spp. is sometimes associated with less severe lung function loss (12, 14,
31, 46), but that some genera of Streptococcus, including the Streptococcus anginosus
group, may facilitate exacerbation (25–27). Our cross-sectional analysis highlights the
positive aspect of patients carrying the community dominated by Streptococcus; subjects
whose airway microbiomes were characterized as Streptococcus-dominated tended to
have better lung function, as shown in Fig. 4A. Clusters differ significantly in ppFEV1 after
correcting for age in this model. Streptococcus-dominated samples tended to come from
younger subjects (Fig. 4B).
Communities observed in subjects with mild versus moderate/severe disease
are similar. Findings in the cross-sectional data (Fig. 4A and B) are consistent with pre-
vious reports showing that communities dominated by Pseudomonas tend to be asso-
ciated with older subjects and reduced lung function. Given that young, healthier
pwCF tend to have sputum communities dominated by Streptococcus led to the hy-
pothesis that people with such Streptococcus-dominated communities ultimately tran-
sition to communities dominated by Pseudomonas as they age. To probe this idea, we
used a longitudinal data set to assess how communities changed in the 24 subjects
TABLE 1Mapping the clusters back to the data sets
Cluster no. Mnemonic Carmody Cuthbertson
1 Str.D 45 1
2 Pa.D 0 27
3 Oth.D 19 18
4 Pa.M1 19 8
5 Pa.M2 1 29
Hampton et al.














































detailed in Table 2, for whom there are 10 or more longitudinal samples collected for
times periods ranging from ;6 to 10 years (average of;8 years).
For this analysis, we used supervised machine learning to track community type
changes in individuals with CF through time. Briefly, we used random forests (47) to
identify features that reliably classify a sample as belonging to one of the five previ-
ously identified communities. This classifier enabled us to identify the community type
of 346 16S rRNA gene amplicon data sets from 24 subjects that were observed across
many years (18). This longitudinal data set included 16S rRNA gene amplicon data set
measurements made in different clinical states (baseline, exacerbation, treatment, and
recovery) and includes clinical metadata such as whether a subject had been diag-
nosed as having mild or more severe disease. This approach mapped the 346 16S rRNA
gene amplicon data sets to the four communities shown in Fig. 3, specifically, Str.D.,
Pa.D, Pa.M1, and Oth.D. No samples in the Carmody (18) longitudinal data mapped to
Pa.M2, consistent with the description of the Pa.M2 cluster being specific to the
Cuthbertson (17) data set (see Table 1).
Roughly two or three community types were required to describe any given subject
over time, recapitulating previous reports that the CF airway microbiome is fairly stable
FIG 4 Association of communities with lung function and age. (A) Association of communities with
lung function. Subject-lung function profiles of 5 distinct communities. Box and whisker plot comparing
ppFEV1 between Streptococcus-dominated (Str.D), Pseudomonas-dominated (Pa.D), communities dominated
by other genera (Oth.D), Pseudomonas mixed community number 1 (Pa.M1), and Pseudomonas mixed
community number 2 (Pa.M2), as shown in Fig. 3A. Communities sharing a common letter are not
significantly different; those with no letter in common differ significantly (Tukey honest significant
difference, P, . 05). For example, subjects with Str.D communities had higher ppFEV1 than those
with any other community type. (B) Association of communities with age. Subject-age profiles of 5
distinct communities. Box and whisker plot comparing age between Streptococcus-dominated (Str.
D), Pseudomonas-dominated (Pa.D), communities dominated by other genera (Oth.D), Pseudomonas
mixed community number 1 (Pa.M1), and Pseudomonas mixed community number 2 (Pa.M2), as
shown in Fig. 3A. Communities sharing a common letter are not significantly different; those with
no letter in common differ significantly (Tukey honest significant difference, P, . 05). For example,
subjects with Str.D communities were younger than those with Pa.D communities or Pa.M2
communities but did not differ significantly in age from subjects with Oth.D or Pa.M1 communities.
Bacterial Community Stability and CF Lung Disease














































over time (15, 18, 19, 39) but may shift in structure around the time of exacerbation or
in response to antibiotic therapy (23, 39). We did not observe large differences in com-
munity types between subjects with mild disease compared to moderate/severe dis-
ease either as a function of subject (Fig. 5A) or disease state (Fig. 5B). For example, sub-
ject 117 was observed 15 times to show a Streptococcus-dominated community (Str.D)
and 5 times to show the Pseudomonas mixed community number 1 (Pa.M1).
We did note some associations. For example, domination by a pathogen other than
Pseudomonas (Oth.D) was associated with decreased probability of being observed in
the baseline state (P value = 0.004, odds ratio 0.43, Fisher’s exact test). Furthermore, de-
spite similarities, subjects with mild disease did differ from those with moderate/severe
disease in specific ways. Subjects with mild disease were more likely to be observed
having a community classified as Pa.M1 (P value = 0.02, odds ratio = 1.69, Fisher’s exact
test) and more likely to be observed in the baseline state (P value = 3.1e-06, odds
ratio = 2.8, Fisher’s exact test) than people with moderate/severe disease.
Interestingly, we note that people with mild disease have bacterial communities that are
more stable over time based on being observed in a specific community category (Fig. 5).
We tested this association using a continuous variable by calculating Bray-Curtis dissimilarity
for all pairwise comparisons of samples taken from any given subject over time. As shown in
Fig. 6A, communities from subjects with mild disease were less dissimilar to each other than
communities from subjects with moderate/severe disease, suggesting that variation in com-
munity composition is associated with worse disease outcomes.
As a second approach to assess the association between community stability and
clinical outcome, a Markov chain analysis was performed to track subjects and their
associated community types across time. Markov models simplify dynamic systems by
representing them as a set of finite states and transitions between these states. With
enough data, the geometry of these systems (i.e., states that are connected to each
other, indicating the possibility of a transition) can be determined. In this context,
Markov models can be used to identify parallels between our longitudinal cohort and
accepted models of ecological succession in the cystic fibrosis airway (48).
TABLE 2 Characteristics of 24 subjects with at least 10 longitudinal samplesa
Isolate Aggressiveness n Period (yr) Median age Median FEV1 Clinical statesb FEV1/yrc
75 Moderate/Severe 16 8.99 14.9 32.5 R, E, T, T, E, R, B, B, R, T, E, B, B, R, B, R 22.23
139 Moderate/Severe 15 6.64 15.1 34 B, B, B, T, R, T, B, B, B, B, R, B, T, T, R 25.17
94 Moderate/Severe 13 9.16 17.2 39 T, T, E, E, T, B, E, B, B, B, B, R, R 1.56
229 Moderate/Severe 11 7.27 19.2 34 R, R, R, B, B, T, R, B, T, B, B 24.50
52 Moderate/Severe 18 9.74 23.0 43.5 T, E, R, R, T, R, R, B, R, R, B, E, E, B, B, B, E, T, R, R 21.84
179 Moderate/Severe 24 8.66 23.8 41 B, E, T, T, B, E, T, R, B, B, E, B, R, R, E, R, T, B, T, E, R, B, E, E 23.08
159 Mild 11 7.97 24.3 82 B, B, B, E, B, B, B, B, B, B, R 21.20
87 Mild 17 7.54 25.0 82 T, T, R, B, E, B, B, B, B, B, R, T, R, B, R, B, B 1.84
160 Mild 13 8.01 25.2 73 B, T, B, B, R, B, R, B, R, B, T, E, B 0.79
142 Moderate/Severe 20 10.14 25.4 67 B, T, T, T, T, E, B, R, T, T, E, E, R, B, T, E, B, R, T, E 21.16
141 Mild 12 8.91 26.3 85.5 R, E, R, B, B, B, R, T, B, R, B, T 20.20
124 Moderate/Severe 18 10.24 26.3 54.5 B, B, T, B, T, B, E, T, B, E, B, E, B, E, T, B, E, B, B 21.00
147 Moderate/Severe 18 8.17 27.2 36.5 B, R, E, E, B, B, B, B, B, T, R, T, T, T, B, B, R, E 23.73
209 Moderate/Severe 16 7.87 28.0 37.5 T, B, T, B, E, T, R, E, R, R, R, T, R, R, B, R 26.97
53 Mild 10 5.35 28.6 69.5 E, R, T, E, B, E, B, E, B, NA, NA 1.55
182 Mild 14 5.69 29.0 83.5 T, B, R, E, E, B, B, B, B, B, B, E, E, E 22.28
118 Mild 10 7.33 30.3 58.5 E, T, B, R, B, B, B, T, R, E 21.33
244 Mild 10 6.42 30.8 74.5 E, R, B, B, R, B, B, B, E, B 22.23
222 Mild 10 7.47 33.5 97 B, R, B, T, B, T, B, B, B, NA 20.21
136 Mild 15 7.6 36.8 57 B, R, B, E, B, B, T, R, B, R, E, E, B, T, B 22.99
119 Mild 14 7.72 37.1 36 E, B, T, B, B, B, B, T, B, B, B, R, B, B 23.42
195 Mild 11 8.24 41.4 54 E, B, E, E, B, E, B, T, R, B, R 0.45
50 Mild 10 6.27 43.5 70.5 B, E, R, B, E, B, B, B, B, R 22.27
117 Mild 20 9.72 49.6 51 E, E, B, R, B, E, B, E, T, T, B, T, B, E, B, E, T, T, B, B 20.31
aDisease aggressiveness for each subject was based on publicly available metadata; n represents the number of sputummicrobiomes available for each subject, observed
over the period, given in years.
bClinical states observed: B, baseline; E, exacerbation; T, treatment; R, recovery.
cLinear regression estimates of the annual change in FEV1 percent predicted for each subject shown at far right. The table is sorted by increasing median age.
Hampton et al.














































Certain aspects of succession in the CF airway are well accepted; airways begin
mostly sterile, are colonized by bacteria from the environment, and develop unique
community structures in different pwCF. These communities are surprisingly stable in
the short term but, over longer periods, lung function and diversity tend to decrease
(31) as a typical CF pathogen becomes increasingly dominant (17). What is less well
understood is the role played by genera that are not typically identified as CF airway
pathogens, and how different communities might affect CF disease, e.g., by causing
pulmonary exacerbations. The climax-attack model (49) proposes the existence of rela-
tively benign climax communities and attack communities that cause exacerbations
and remodeling. Interestingly, the model proposes that these two communities can
coexist in the same subject and may contain substantially similar genera. The more vir-
ulent attack community is thought to be metabolically distinct, and to be enriched in
genera that can flourish in oxygen-deprived conditions (28). Therefore, remaining in
the less virulent climax community should be advantageous, even if climax community
is associated with older age and reduced lung function. Our data support this assess-
ment, although it should be noted that our communities were selected by a data-
driven process and were not specifically designed to reflect climax or attack commun-
ities per se. In addition, the Str.D community, which would be most similar to previ-
ously described attack communities, did not significantly predict exacerbation state, as
shown in Fig. 5B.
Nonetheless, the dynamic community structure detected by Markov chains is broadly
consistent with cyclical behavior predicted by the climax-attack model, and the proposition
FIG 5 Association of clusters across samples and disease state. (A) Frequency of observing various community
types in subjects designated having mild or moderate/severe disease. Subjects with mild disease (n= 14, left)
are compared to subjects with moderate/severe disease (n= 10, right). “Subject identifier” corresponds to
“isolate” in Table 2, a field provided in the Carmody (18) data set. Community types identified in these
longitudinal samples were deemed similar to those in Fig. 3A by the random forest classifier. (B) Frequency of
observing various clinical states for the 14 subjects with mild disease aggressiveness (left) and the 10 subjects
with moderate/severe disease (right), as shown in Table 2. Clinical states are defined as B, baseline; E,
exacerbation; T, treatment; and R, recovery. Community types identified in these longitudinal samples were
deemed similar to those in Fig. 3A by the random forest classifier.
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that remaining in a stable climax community may be preferable to undergoing changes in
community structure, as follows. Subjects with mild disease (Fig. 6B) were observed in three
discrete states: Pa.M1, Str.D, and Oth.D. Of these, Pa.M1 is most like what has been described
as a CF climax community, and Str.D is most like what has been described as an attack com-
munity. Stability in a Markov chain is defined as a transition to the current state and is
denoted by a loop back to the same node. Figure 6B shows that subjects in the Pa.M1 state
had the highest probability of remaining in the same state (0.73), consistent with concept
Pa.M1 being a climax community. Subjects with mild disease (Fig. 6B) were significantly
more likely to remain in Pa.M1 than subjects with moderate/severe disease (red arrow in 6B:
* indicates P=0.03, Fisher’s exact test, odds ratio 1.78), which is consistent with the climax-
attack model’s prediction that stability in a climax state protects lung function. Transitions
from Pa.M1 to Str.D may represent transitions from a climax state to an attack state.
One reason subjects with mild disease might appear more stable in this model is
that they were more frequently observed, leaving less time to elapse during which a
community might change in structure. However, greater stability in mild subjects can-
not be attributed to an insufficient amount of time having passed between measure-
ments to observe a change, because their average time between measurements
(0.64 years) was somewhat longer than the average time between measurements in
moderate/severe subjects (0.55 years), though this difference did not achieve signifi-
cance (P value = 0.16, Welch’s t test).
Our Markov chain analysis also provides support for other aspects of the climax-
attack model, though these relationships did not achieve statistical significance.
Communities that were dominated by Streptococcus (Str.D) were most likely to succeed
Oth.D communities. This suggests that Str.D communities in sputum, likely descend-
ants of pioneers that migrated from the mouth, may displace climax communities
dominated by Pseudomonas or other traditional CF pathogens such as Burkholderia or
Achromobacter. This finding is therefore generally consistent with both the climax-
attack model and the island biogeography model (50).
It is interesting that the Pa.D community was detected in subjects with severe dis-
ease (Fig. 6C) but not in subjects with mild disease (Fig. 6B), and that the Pa.D state
was not stable. This observation suggests that in our system, mixed communities with
high levels of Pseudomonas behave more like climax communities than communities
with the highest levels of Pseudomonas. Since the Pa.D community was rarely
FIG 6 Support for the climax-attack model. (A) Median within-subject pairwise distances (Bray-Curtis dissimilarity) for n= 14 subjects
with mild disease aggressiveness (left) and n= 10 subjects with moderate/severe disease (right) as shown in Table 2. Subjects with
mild disease had samples that were significantly more similar to each other (* signifies P, 0.05, Wilcoxon rank sum exact test). (B)
Markov chain diagram for community transitions in subjects with mild disease (see Table 2). Each node in the diagram (orange
circles) represents the state of being observed with a specific bacterial community. Edges leading from each node represent possible
transitions, including the possibility of observing the same community again (loop). Numbers on arrows are estimates of the
probability of taking a specific path. Subjects with mild disease were significantly more likely to remain in Pa.M1 than subjects with
moderate/severe disease (red arrow; * indicates P= 0.03, Fisher’s exact test, odds ratio 1.78). (C) Markov chain diagram for community
transitions in subjects with moderate/severe disease (see Table 2). Each node in the diagram (orange circles) represents the state of
being observed with a specific bacterial community. Edges leading from each node represent possible transitions, including the
possibility of observing the same community again (loop). Numbers on arrows are estimates of the probability of taking a specific
path.
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observed, it is not possible to make statistical statements about its possible association
with disease state or disease aggressiveness. However, it is possible that our data
reflect a biological constraint; perhaps mild disease is incompatible with very high lev-
els of Pseudomonas, even for brief periods.
DISCUSSION
We present two major findings in this report. First, the previously reported climax-
attack model postulates that an attack community composed of genera like Streptococcus,
Veillonella, and Porphyromonas perturbs a climax community dominated by Pseudomonas
and Staphylococcus (28), resulting in a metabolic shift toward fermentation and decreasing
pH. These conditions are more favorable to fermentative bacteria like Prevotella, Veillonella,
Streptococcus, Rothia, and Granulicatella (28). Our observation that mild disease is associ-
ated with community stability, and that stability is associated with a Pseudomonas-domi-
nated community, are therefore consistent with the climax-attack model of CF.
Second, we have shown that a relatively small number of CF microbiome types
explain patient differences in lung function, and that they explain these differences
much better than single variables such as the relative abundance of Pseudomonas, age,
or Simpson diversity. This finding is important because developing interventions to
treat the community as the pathogenic unit will require a reasonable number of exper-
imentally tractable model communities. Without such models, we would be faced with
a dizzying array of patient differences. Fortunately, the airway community in a pwCF
over multiple samplings generally looks more like “self” than any other patient when
using relative abundance of bacteria as a metric of what defines a community, thereby
increasing the likelihood of identifying an in vitro model that might help design more
effective treatment regimens for a pwCF that has a similar community composition.
Our findings raise the question of what combinations of abundant microbes
(Pseudomonas, Streptococcus, and Staphylococcus) and less abundant community
members (i.e., anaerobic, fermentative organisms) really matter. Does it matter if a
patient has 90% Pseudomonas versus 80% or 70%? Intriguingly, Pseudomonas, often
listed as the quintessential CF pathogen, is highly abundant in long-lived people
with CF, i.e., it is an aspect of a “survivor phenotype” (51). Alternatively, does it matter
if the dominant microbe in a community is Streptococcus rather than Pseudomonas, or if
the minor players are Prevotella versus Veillonella versus Gemella? Although unsupervised
machine learning cannot answer these questions with precision, we have demonstrated
that as few as five communities may represent a useful starting point, as pwCF with a par-
ticular community type experience significantly similar lung function as measured by
ppFEV1.
There are several critical factors and caveats to consider in light of the interpreta-
tions we make here. First, although a gap statistic suggests five communities may be
optimal for the cross-sectional data set used here, one should avoid construing “five”
as the number of distinct populations in the CF community. Children younger than
eight were not included in this study, and it is possible that broad sampling of young
pwCF would have enabled us to identify additional clusters. In the same vein, although
cluster 3 (Oth.D) contains subjects that were dominated by genera other than
Pseudomonas, it is understood that broader sampling of this group would create addi-
tional clusters for each genus in cluster 3. Nonetheless, some of the findings here mir-
ror the conclusions from previous studies with smaller data sets (12, 15, 38). Second,
this study includes both cross-sectional and longitudinal observations of airway micro-
biomes and associated clinical parameters, enabling us to identify associations
between them. However, this type of study cannot prove causation. Indeed, our inter-
pretation of the data here should rightly be viewed as hypotheses to be tested either
via additional clinical studies or in the laboratory. Third, and related to the previous
point, the most useful aspect of this work is that it does set a framework for hypothesis
testing; for example, can we build the communities we observe here in vitro and assess
their function (i.e., are some clusters of microbes more/less cytotoxic or more/less
Bacterial Community Stability and CF Lung Disease














































recalcitrant to antibiotics)? Alternatively, are similar communities associated with posi-
tive/negative health outcomes in other cohorts of pwCF or in other disease settings?
For example, a recent report by Frey et al. (29) concludes that airway diversity is a bio-
marker of lung disease severity that links dysbiosis to lung function decline in pwCF.
They observed a negative correlation between inflammatory cytokine secretion and
airway community diversity, suggesting that more diverse communities are for some
reason more salubrious than less diverse communities (a common but unexplained
finding across many microbiome studies). Using a slightly different unsupervised
approach to identify CF airway communities (i.e., hierarchical clustering of Unifrac dis-
tances), these investigators found that high diversity maps to an oropharyngeal-like
community typically found in younger people. The authors carefully avoid making the
claim that bacterial diversity reduces inflammation, although others have reported this
association (43) or found a positive association between higher lung function and
increased bacterial diversity (14, 17). The diverse, oropharyngeal-like community identi-
fied by Frey and colleagues is characterized by anaerobes like Prevotella and Veillonella
and aerobic commensals, including Neisseria and Streptococcus, making it very similar to
the Streptococcus-dominated community (Str.SD) identified in this report (Fig. 3). Of note,
our Str.D community was also associated with higher lung function (Fig. 4A) and relative
youth (Fig. 4B) in pwCF. Thus, orthogonal approaches appear to converge on similar con-
clusions as to community composition associated with less severe health outcomes.
The findings here and reported by Frey et al. (29) and others (14, 43, 46) raise the
question of whether remodeling CF airway communities to make them more diverse
and more similar to the oropharyngeal communities found in younger people with
higher lung function, if possible, might improve outcomes in CF. There are several rea-
sons to question the wisdom of attempting to turn back the hands of time in older
subjects and enhance the abundance of oropharyngeal flora in their airways. First, as
described above, it is possible that the introduction of diversity into an established
community (for example, one dominated by Pseudomonas) would destabilize the com-
munity and lead to enhanced inflammation, as suggested by the climax-attack model
of CF (49). Second, as demonstrated by Muhlebach et al. (52), inflammation increases
when pediatric pwCF are first colonized by oropharyngeal flora; although this finding
should not be surprising, it is worth pointing out that the best airway community is
probably no community at all. Third, even in adults, increased diversity is not uniformly
benign. Studies by Raghuvanshi et al. (24) show a linear increase in the microbiome
alpha-diversity and in the log ratio of anaerobes to pathogens 2 weeks before a pulmo-
nary exacerbation, confirming similar observations by Carmody et al. (18) showing that
bacterial community diversity and the relative abundance of anaerobes increased dur-
ing exacerbations, i.e., before antibiotic treatment. Others have shown that treating
adults with antibiotics primarily affects taxa other than classic CF pathogens (53, 54),
and that antibiotics reduce the abundance of Streptococcus, Prevotella, and Veillonella,
but not Pseudomonas, the ostensible target of treatment. Collectively, then, the results
cited support the somewhat surprising conclusion that oropharyngeal flora are associ-
ated with worse airway disease, and that treatments work because they reduce the
abundance of oropharyngeal genera.
Finally, as mentioned above, we present just one approach for analyzing the extant
microbial community data associated with CF airway infections, but an approach that
has both statistical support and practical utility. That is, it is likely that only controlled
experiments using model communities in a laboratory setting or in animals can unravel
the mechanistic role played by oropharyngeal-like flora in an established adult micro-
biome (14, 25, 27, 43), thereby enhancing our understanding of the functional conse-
quences of community composition. That is, we have identified 5 communities com-
prising 10 genera, which present an experimentally tractable number of communities
and microbes. As another example, Crabbe et al. (55) recently reported using a nine-
member community for in vitro studies. Going forward, this and other studies can help
Hampton et al.














































inform the nature of laboratory model communities used to probe the hypotheses we
and others have developed by analyzing clinical data sets.
MATERIALS ANDMETHODS
Data processing. Publicly available 16S rRNA gene amplicon library sequence reads and associated
metadata from recent studies by Carmody et al. (PRJNA423040) (18) and Cuthbertson et al. (PRJEB30646)
(17) were downloaded from Bioproject (https://www.ncbi.nlm.nih.gov/bioproject/). Reads in fastq format
were mapped to unique bacterial genera using QIME2 (56).
Cross-sectional data set. We assembled a cross-sectional data set by combining baseline data (i.e.,
not exacerbating, not receiving treatment for exacerbation) set from 167 unique pwCF, composed of 84
from the Cuthbertson et al. study (17) and 83 from the Carmody study (18). In those instances where
more than one baseline sample was available from a given subject, the first sample taken was used, to-
gether with metadata (e.g., ppFEV1). The two data sets were similar but not identical in terms of age and
lung function. The 84 subjects included in the cross-sectional data set from the Carmody et al. study (18)
were slightly younger, with a mean age of 25.66 10.0 standard deviation (SD) compared to a mean age
of 30.276 10.9 SD. Operational taxonomic unit (OTU)-level mapping and metadata for the two cross-
sectional data sets (17, 18) is provided in Table S1 and Table S2 in the supplemental material.
Samples in the two studies were processed using somewhat different protocols. The Carmody proto-
col involved breaking down bacterial cell walls by bead beating, DNA extraction using a MagNA Pure
nucleic acid purification platform, amplification of the V3, V4, and V5 hypervariable regions, and Roche
454 pyrosequencing. The Cuthbertson protocol included pretreatment with propidium monoazide prior
to DNA extraction to prevent sequencing of reads from dead bacteria. This step alone should create sys-
tematic differences between the two data sets, even if one assumes identical starting material. Two
other differences between the two protocols would also be predicted to add to systematic differences
between the two data sets, namely, amplification of different hypervariable regions (V1 to V2) and
sequencing on the Illumina MiSeq platform using V3 chemistry. Not surprisingly, a permutational multi-
variate analysis of variance (PERMANOVA) of Bray-Curtis dissimilarity between the two data sets esti-
mates that about 18% of the variability in the cross-sectional data set is explained by the study from
with a sample originated (r2 = 0.181, P, 0.0001). Since subjects in the two studies were of slightly differ-
ent ages and were treated in different health care systems (essentially, United States in one case and
Europe in the other), it is likely that systematic differences between communities reflect both biological
and technical differences. Although it is not possible to assess the relative contribution of technically
and biologically derived variability in our cross-sectional data, we can say that more than 82% of the var-
iability in these data arose from nontechnical sources. In short, although technical differences probably
add noise to this meta-analysis of microbiome data, large biologically driven signals should be detecta-
ble, as others have shown (45).
Longitudinal data set. The longitudinal data set was a subset of samples from the Carmody et al.
(18) study, specifically, 346 16S rRNA gene amplicon data sets from 24 subjects that were observed at
least 10 times. Age at time of sampling ranged from 11 to 54, with median of 27 and an interquartile
range of 8. Lung function (ppFEV1) of subjects in the longitudinal data set ranged from 9% to 123%,
with a median of 50 and an interquartile range of 36. Longitudinal subjects are more fully described in
Table 2. OTU level mapping and metadata for the longitudinal data set (18) is provided in Table S3. Our
longitudinal data analysis contrasted subjects with mild disease with those classified as having moder-
ate/severe disease, classifications that were annotated by Carmody et al. (18) using a method developed
by Schluchter et al. (57). This classification system uses annual changes in lung function to predict what
a subject’s lung function would be at 20 years of age. For example, a person whose rate of decline dur-
ing childhood predicts a ppFEV1 of 35% by age 20 would be classified as having severe disease.
Statistical analyses. Data analysis was performed in R 4.0.1 (https://www.R-project.org/). Bray-Curtis
dissimilarity was calculated using ecodist (58). Simpson diversity was calculated with vegan 2.5-7 (59).
Clustering was performed using kmeans in base R and clusters were visualized and gap analysis was per-
formed using factoextra 1.0.7 (60). Random forests were generated using randomForest 4.6-14 (61).
Discrete Time Markov chains were determined using the markovchain package 0.8.5-4 (62).
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, CSV file, 0.1 MB.
SUPPLEMENTAL FILE 2, CSV file, 0.1 MB.
SUPPLEMENTAL FILE 3, CSV file, 0.3 MB.
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